Mani Subramanian
Overview
Explore the profile of Mani Subramanian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
736
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu Z, Gnouamozi G, Rueger S, Shea P, Buti M, Chan H, et al.
Am J Hum Genet
. 2024 May;
111(6):1018-1034.
PMID: 38749427
Evolutionary changes in the hepatitis B virus (HBV) genome could reflect its adaptation to host-induced selective pressure. Leveraging paired human exome and ultra-deep HBV genome-sequencing data from 567 affected individuals...
2.
Louie T, Louie K, DenHartog S, Gopishetty S, Subramanian M, Arnold M, et al.
Microb Cell Fact
. 2021 Feb;
20(1):50.
PMID: 33618706
Background: Xylitol is a five-carbon sugar alcohol that has numerous beneficial health properties. It has almost the same sweetness as sucrose but has lower energy value compared to the sucrose....
3.
Agrawal T, Gaggar A, Subramanian M, Kottilil S, Choudhary A, Rao P, et al.
Arab J Gastroenterol
. 2020 Oct;
21(4):267-272.
PMID: 33071176
Background And Study Aims: Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver diseases. This study aimed to determine the association between polymorphisms in interleukin...
4.
Kolipinski M, Subramanian M, Kristen K, Borish S, Ditta S
J Environ Public Health
. 2020 Oct;
2020:8184614.
PMID: 33014081
This report synthesizes and evaluates published scientific literature on the environmental occurrence and biomagnification of mercury with emphasis on the San Francisco Bay Area (SFBA), California. Mercury forms various compounds,...
5.
Yuen L, Revill P, Rosenberg G, Wagner J, Littlejohn M, Bayliss J, et al.
J Viral Hepat
. 2020 May;
27(10):1061-1070.
PMID: 32384174
Nucleos(t)ide analogues (NUC) treatment prevents progression of liver fibrosis in subjects with chronic hepatitis B (CHB). However, risk of hepatocellular carcinoma (HCC) persists despite viral suppression. Specific HBV variants have...
6.
Walsh R, Hammond R, Yuen L, Deerain J, ODonnell T, Leary T, et al.
Liver Int
. 2019 Aug;
39(11):2066-2076.
PMID: 31379058
Background And Aim: Functional cure is the major goal of chronic hepatitis B (CHB) therapy though few biomarkers predict this outcome. HBsAg epitope occupancy can be influenced by therapeutic and...
7.
Podlaha O, Wu G, Downie B, Ramamurthy R, Gaggar A, Subramanian M, et al.
PLoS One
. 2019 Jul;
14(7):e0220376.
PMID: 31356634
Hepatitis B infection is a world-wide public health burden causing serious liver complications. Previous studies suggest that hepatitis B integration into the human genome plays a crucial role in triggering...
8.
Podlaha O, Gane E, Brunetto M, Fung S, Chuang W, Pan C, et al.
Sci Rep
. 2019 Jul;
9(1):10529.
PMID: 31324819
Despite the high global prevalence of chronic hepatitis B (CHB) infection, datasets covering the whole hepatitis B viral genome from large patient cohorts are lacking, greatly limiting our understanding of...
9.
Ahn S, Marcellin P, Ma X, Caruntu F, Tak W, Elkhashab M, et al.
Dig Dis Sci
. 2018 Oct;
64(1):285-286.
PMID: 30324553
The original version of this article unfortunately contained affiliation and textual errors. This has been corrected with this erratum.
10.
Ahn S, Marcellin P, Ma X, Caruntu F, Tak W, Elkhashab M, et al.
Dig Dis Sci
. 2018 Aug;
63(12):3487-3497.
PMID: 30136045
Background And Aims: Hepatitis B surface antigen (HBsAg) loss is the ideal clinical endpoint but is achieved rarely during oral antiviral treatment. A current unmet need in CHB management is...